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Anti-HIV activity mediated by natural killer and CD8+ cells
after toll-like receptor 7/8 triggering
Abstract
We previously found that triggering TLR7/8 either by single stranded HIV RNA or synthetic
compounds induced changes in the lymphoid microenvironment unfavorable to HIV. In this study, we
used selective TLR7 and 8 agonists to dissect their contribution to the anti-HIV effects. While triggering
TLR7 inhibited efficiently HIV replication in lymphoid suspension cells from tonsillar origin, its effect
was inconsistent in peripheral blood mononuclear cells (PBMC). In contrast, triggering TLR8 showed a
very prominent and overall very consistent effect in PBMC and tonsillar lymphoid suspension cells.
Depletion of dendritic cells (DC), Natural killer cells (NK) and CD8+ T-cells from PBMC resulted in
the reversal of TLR8 induced anti-HIV effects. Especially noteworthy, depletion of either NK or CD8+
T-cells alone was only partially effective. We interpret these findings that DC are the initiator of
complex changes in the microenvironment that culminates in the anti-HIV active NK and CD8+ effector
cells. The near lack of NK and the low number of CD8+ T-cells in tonsillar lymphoid suspension cells
may explain the lower TLR8 agonist's anti-HIV effects in that tissue. However, additional cell-type
specific differences must exist since the TLR7 agonists had a very strong inhibitory effect in tonsillar
lymphoid suspension cells. Separation of effector from the CD4+ target cells did not abolish the
anti-HIV effects pointing to the critical role of soluble factors. Triggering TLR7 or 8 were accompanied
by major changes in the cytokine milieu; however, it appeared that not a single soluble factor could be
assigned for the potent effects.These results delineate the complex effects of triggering TLR7/8 for an
efficient antiviral defense. While the ultimate mechanism(s) remains unknown, the potent effects
described may have therapeutic value for treating chronic viral diseases. Notably, HIV replication is
blocked by TLR triggering before HIV integrates into the host chromosome which would prevent the
establishment or maintenance of the latent reservoir.
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Abstract
We previously found that triggering TLR7/8 either by single stranded HIV RNA or synthetic compounds induced changes in
the lymphoid microenvironment unfavorable to HIV. In this study, we used selective TLR7 and 8 agonists to dissect their
contribution to the anti-HIV effects. While triggering TLR7 inhibited efficiently HIV replication in lymphoid suspension cells
from tonsillar origin, its effect was inconsistent in peripheral blood mononuclear cells (PBMC). In contrast, triggering TLR8
showed a very prominent and overall very consistent effect in PBMC and tonsillar lymphoid suspension cells. Depletion of
dendritic cells (DC), Natural killer cells (NK) and CD8+ T-cells from PBMC resulted in the reversal of TLR8 induced anti-HIV
effects. Especially noteworthy, depletion of either NK or CD8+ T-cells alone was only partially effective. We interpret these
findings that DC are the initiator of complex changes in the microenvironment that culminates in the anti-HIV active NK and
CD8+ effector cells. The near lack of NK and the low number of CD8+ T-cells in tonsillar lymphoid suspension cells may
explain the lower TLR8 agonist’s anti-HIV effects in that tissue. However, additional cell-type specific differences must exist
since the TLR7 agonists had a very strong inhibitory effect in tonsillar lymphoid suspension cells. Separation of effector from
the CD4+ target cells did not abolish the anti-HIV effects pointing to the critical role of soluble factors. Triggering TLR7 or 8
were accompanied by major changes in the cytokine milieu; however, it appeared that not a single soluble factor could be
assigned for the potent effects. These results delineate the complex effects of triggering TLR7/8 for an efficient antiviral
defense. While the ultimate mechanism(s) remains unknown, the potent effects described may have therapeutic value for
treating chronic viral diseases. Notably, HIV replication is blocked by TLR triggering before HIV integrates into the host
chromosome which would prevent the establishment or maintenance of the latent reservoir.
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Introduction
Pattern recognition receptors act as sentinels against microor-
ganisms [1]. They recognize conserved motifs of microorganisms
and trigger distinct signaling pathways that result in coordinated
cellular changes critical to the immediate innate defense and the
generation of adaptive immune response.
Toll-like receptors (TLR) are an essential family of pattern
recognition receptors [1]. They can be grouped by their
preferences for structural motifs. TLR3, 7, 8, and 9 are implicated
in anti-viral defense [1,2]. TLR3 recognizes double-stranded viral
RNA [3], TLR7 and 8 recognize single-stranded viral RNA [4,5]
and TLR9 unmethylated DNA rich in cytosine-guanosine motifs
from bacteria and viruses [6]. TLR3 is expressed on myeloid
dendritic cells (MDC), TLR7 and 9 on plasmacytoid dendritic cells
(PDC), and TLR8 on MDC and monocytes [7,8]. While the
transduction pathways of individual TLRs are well described [9],
the overall effects of TLR triggering on the lympho-reticular
system and on viral diseases remain largely unknown.
Compounds triggering distinct TLR may be of great value for
targeted immunomodulation of viral diseases, including HIV [10].
The complex changes from triggering TLR may be more
beneficial than administration of single cytokines. In fact, human
studies examining treatments with distinct cytokines have rather
been discouraging [11]. A detailed mechanistic examination is
certainly required for the targeted use of compounds triggering
TLR.
We previously reported that the TLR7/8 agonist R-848 or HIV
ssRNA has immediate anti-HIV activities [12]. Furthermore,
TLR7/8 agonists which were given as vaccine adjuvants in
concert with HIV proteins were able to impact on the magnitude
and quality of anti-HIV CD8+ T-cell responses [13,14]. Thus,
triggering TLR7/8 stimulates the innate as well as the adaptive
immune response; this unique property makes them, at least
theoretically, superior to cytokines, which are conventionally given
as single agent and either act on the innate or the adaptive arm of
the immune system. Thus, triggering TLR7/8 may represent an
ideal therapeutic strategy for immunomodulation stimulating
multiple arms of the immune response.
In the previous work, we examined the synthetic compound R-
848, which triggers TLR7 and 8. Since TLR7 is preferentially
expressed on PDC [8], the major producer of IFN-a, TLR7
triggering is believed to be a key factor in the overall anti-viral
response. However, IFN-a did not have a major role in the anti-
HIV activity that we observed since its neutralization did not
reverse R-848’s anti-HIV effect. To differentiate the individual
contributions of triggering TLR7 and 8 to the anti-HIV activity
requires agonists that specifically and efficiently trigger the
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corresponding TLR. Because TLR8 does not function in
mice[15], this pathway has been less well studied, and its biologic
significance is largely unknown.
In the present study, we used agonists that specifically trigger
each pathway to characterize the individual contributions of
TLR7 and 8 signaling to the overall anti-HIV effect. Our findings
suggest novel strategies for anti-HIV therapies.
Results
Anti-HIV activity of triggering TLR7 and/or 8 depends on
the origin of lymphoid tissue
We first determined the optimal working concentration of the
TLR7 and/or 8 agonists; briefly, these agonists were added to
tonsillar lymphoid suspensions cells in a range of 0.1–30 mmol; the
tissue was infected two days later. HIV replication was monitored by
measuring viral capsid p24 antigen (p24 Ag) in the supernatant. We
also assessed the dose-dependent effects on cell viability of these TLR
agonists. We found that the optimal working concentration was
3 mmol (Fig. 1A–C) which had a strong inhibitory effect on HIV
replication while it had no negative effect on cell viability.
The HIV strains, NL4-3 (X4-tropic) and 49.5 (R5-tropic) we used
replicates vigorously in untreated tonsillar lymphoid suspension cells
and PBMC [12]. In tissue-matched tonsillar lymphoid suspension
samples, triggering TLR7 or 7/8 resulted in substantial inhibition of
NL4-3 replication, i.e., 3M-001: 64% (50.2 to 77.2) (median
inhibition (25% to 75 percentile)); R-848: 73.5% (70.2 to 81.5))
(Fig. 1 D). Although less effective, triggering TLR8 still yielded an
inhibition with a median of 46.9% (40.8 to 56.2). In contrast, in
PBMC, triggering TLR8 resulted in substantially higher anti-HIV
activity than triggering TLR7 (median inhibition 3M-001: 2.5%
(254 to 60.2) vs 79.5% (65.3 to 89)) (Fig. 1E). Not unexpected, the
TLR7/8 agonist R-848 again had high levels of anti-HIV activity
(median inhibition: 79.1% (87.1 to 69.3)). In other experiments, we
verified that the changes in the microenvironment induced by TLR7
or 8 agonists had similar anti-HIV effects on a number of HIV
strains with distinct co-receptor selectivity (anti-HIV activity
subsequent to 3M-001 in tonsillar lymphoid suspension cell cultures
infected with JR-CSF: 96.67% (96.42 to 96.72), 49.5: 93.5% (95.4 to
97.34), 89.6: 81% (75.6 to 86.4); anti-HIV activity subsequent to 3M-
002: JR-CSF: 94.9% (94.7 to 95.2), 49.5: 91.4% (93.6 to 95.9), 89.6:
65% (73.7 to 82.5; n=2; 49.5 and JR-CSF are R5-tropic strains,
89.6 is a dual-tropic strain).
The origin of the lymphoid tissue may be important for the
distinct biologic effects observed. Indeed the cellular composition
differed significantly between PBMC and tonsillar lymphoid
suspension cells (Table 1). Most prominent was the nearly
complete absence of NK and monocytes in tonsillar lymphoid
suspension cell cultures. The percentage of CD4+, CD8+ and B-
cells displayed also marked differences depending on the origin of
the tissue. In contrast, the fraction of PDC and MDC was similar
in PBMC and tonsillar lymphoid suspension cells.
DC are critical for the anti-HIV effects observed
TLR7 and 8 show cell-specific expression with TLR7 expressed
on B-cells and PDC, and TLR8 on monocytes and MDC [7,8].
Based on their sentinel role and the expression of TLR8, we assumed
thatMDC are the most likely target cells responsible for the dramatic
HIV inhibitory effects. Indeed when DC and precursor DC were
depleted from PBMC, HIV replication increased 12-fold and 27-
fold, despite adding the TLR8 and TLR7/8 agonists, respectively.
Notably, we noted a 3-fold increase in lymphoid tissue lacking DC as
compared to unfractionated lymphoid tissue; this 3-fold increase
points to an antiviral action by DC triggered by HIV alone (Fig. 2A).
We observed striking differences of cytokine released in the media
between unfractionated PBMC and PBMC lacking DC indicating
the successful depletion of DC (Table 2). The striking differences
observed is explained by the lack of DC which produce cytokines
[16] as well as by the lack of DC which will activate down-stream
effector cells such as NK cells and CD8+ T-cells [17,18].
Furthermore, there were differences in the cytokine release in
response to the distinct TLR7 and/or 7/8 agonists tested. These
results reflects the subset specific ability of DC to respond to TLR
agonists [8] and underscores the importance of DC within the
complex network of innate immunity. In line with data with R-848
[19], the potency of pure TLR8 agonists to activate monocyte-
derived myeloid dendritic cells (MoMDC) was illustrated by their
characteristic histological changes (Fig. 2B) and the marked increase
of the maturation/activation markers, CD80, 83 and 86 one day
after exposure to the TLR8 agonist 3M-002 (Fig. 2C–E). MoMDC
which have been activated by TLR7 and/or 8 agonists show
substantial induction of a large number of cytokines (Table 3).
NK and CD8 T cells are the main effector cells for the anti-
HIV activity after triggering TLR7 and/or 8
We wanted to assess the role of CD8+ T-cells and NK cells for
their significance in the TLR7/8’s HIV inhibitory activity. For this
purpose, we depleted these cell subsets by using microbeads, added
the TLR7 and/or 8 agonists and infected the cells two days later.
We found that depleting CD8+ T-cells reversed the TLR8 and/or
7/8s’ anti-HIV effects minimally, that depleting NK cells were
more efficient in that sense, but strikingly depleting both
simultaneously resulted in a nearly complete reversal of the anti-
HIV effects (Fig. 3).
Triggering TLR8 and/or 7/8 resulted in activation of CD8+ T-
cells and NK cells, as assessed by expression of the activation
marker CD69, by intracellular staining for IFN-c and TNF-a, by
measuring CD107a, and by their cytotoxic activity against the
NK-responsive cell line K562 (Fig. 4). CD107a is a granular
protein and is exposed at the cellular surface during degranulation
of cytokines and of cytotoxic proteins such as perforin and
granzyme [20]. Staining for CD107, thus, quantifies the
cumulative cytolytic activity of a distinct cell population.
To characterize in depth the NK phenotype leading to the anti-
HIV activity, we quantified a large number of NK-specific cell surface
markers known for as activating or inhibitory receptors by flow-
cytometry. In particular, we hypothesized that TLR7/8 triggering
will favor NK to express activating and less inhibitory receptors.
However, the expression of the activating NK receptor, NKG2D,
was significantly lower subsequent to the exposure of PBMC toR-848
than in the control (control vs R-848: median (minimum–maximum)
% of cells expressing NKG2D 2.9 (2.4–3.4) vs 1.42 (1.04–1.58), n=3,
p=0.007, paired T-test). The levels of expression of other inhibitory
(CD94, KIR2DL2, KIR3DL1, ILT2) and activating receptors
(NKp30, NKp46, NKp44, DNAM-1) on NK cells were similar
irrespective of triggering TLR7/8 (data not shown).
In contrast, triggering TLR7 and/or 7/8 strikingly up-regulated
TRAIL (control vs 3M-001, 3M-002 and R-848: median
(minimum–maximum) % of cells expressing TRAIL: 7.2 (3.8–
14.2) vs 54 (34.3–75.2), 65 (44–73.3), 64 (37.9–79.4); ANOVA
P=0.003, P,0.05, ,0.01 and ,0.01, respectively).
Soluble factors mediate anti-HIV effects after triggering
of TLR7 and/or 8
When effector cells were separated from target cells by transwells,
HIV replication was efficiently inhibited. This finding clearly
indicates that soluble factors have a potent anti-HIV effect (Fig. 5).
TLR8mediated Anti-HIV activity
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Figure 1. Triggering TLR7 and/or 8 results in strong anti-HIV activity that varied with the origin of human lymphatic tissue. Dose-
dependent blocking of HIV by the compounds tested (&= 3M-001, m=3M-002, ¤=R-848) when exposing tonsillar lymphoid suspension cells to (A)
the R5-tropic strain 49.5 (n = 2) or (B) the X4-tropic strain NL4-3 (n = 6 for 3M-001 and 3M-002 and for data points 3, 10, 30 mm, otherwise n = 2). (C) No
toxic effects were noted in lymphoid tissue at 3 mm of any of the TLR agonists, as measured by the WST-1 assay (n = 6). Anti-HIV activities (D) in
tonsillar lymphoid suspension cells and (E) in PBMC. Data obtained with R-848 were partially published before [12]. Data were first analyzed by one-
way analysis of variance and if tested significantly different, by Bonferroni’s multiple comparison test.
doi:10.1371/journal.pone.0001999.g001
TLR8mediated Anti-HIV activity
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Levels of a large number of cytokines and chemokines were increased
after triggering TLR7 and/or 8 (Table 4). Most impressively, IFN-a
increased more than 100-fold after triggering either TLR7 and/or 8.
The TLR agonists 3M-002 and R-848, which trigger TLR8, caused
a more pronounced release of IL-12 and TNF-a than 3M-001.
Furthermore, we observed moderate increases of the b-chemokines.
Some of those cytokines are known to have anti-HIV activities.
To assess the significance of the individual cytokines on HIV
replication, we have used commercially available neutralizing
antibodies to block these cytokines, and followed mainly the
providers’ instructions in regard to the concentration; in any case
we used always concentrations at the upper limit feasible (see
material and method section). We have formal proof that the
neutralization of IFN-a and TNF-a was effective: the efficacy of
the IFN-Ra antibody is shown by the fact that adding this
antibody resulted in higher HIV replication in control cultures
(Fig. 5B). The TNF-a blocking antibody showed complete
suppression of recombinant TNF-a in a transient-transfection
assay using a NFkB reporter assay (data not shown). Furthermore,
there was a tendency that blocking IL-12, -15 and -18 was also
effective in the reversal of TLR7-mediated anti-HIV effects. In
any case, neutralization of individual cytokines or of combinations
of diverse cytokines was not sufficient to reverse the anti-HIV
effects after triggering TLR8 or 7/8 (Table 5). In contrast, the
inhibitory activity in cultures treated with the TLR7 agonist was
partially reversed when adding nAb against the IFN-Ra, pointing
to the known anti-viral role IFN-a has in many settings. To
conclude, the enigma concerning the soluble factor responsible for
the potent TLR7/8 agonists’ anti-HIV effect remains.
HIV replication is blocked after entry but before
integration
For simplicity, HIV replication can be divided into entry, post-
entry, and post-integration steps. Using a cell-cell-based fusion
Figure 2. DC are critical in the generation of the microenvironment unfavorable for HIV replication. (A) Depletion of DC and DC
precursors resulted in reversal of HIV inhibition (n = 2) despite triggering TLR8 and/or 7/8. Represented is the fold increase of HIV replication in PMBC
depleted of DC as compared to matched samples. (B) The TLR agonists 3M-002 and R-848 which trigger TLR8 and 7/8 respectively resulted in
clumping and activation of MoMDC. This was not the case with 3M-001, which triggers solely TLR7. (C–E) Triggering TLR8 or 7/8 resulted in marked
activation of MoMDC as quantified by the cell-surface expression of CD80, CD83, and CD86 (n = 4). Data were first analyzed by one-way analysis of
variance and if tested significantly different, by Bonferroni’s multiple comparison test.
doi:10.1371/journal.pone.0001999.g002
Table 1. Differential cell count in PBMC and tonsillar lymphoid suspension cells in % (avg6std; n = 4).
CD4+ cells CD8+ cells CD19+ cells (B-cells) CD14+ cells (monocytes) CD56+ cells (NK) MDC PDC
PBMC 37.267.5 19.067.5 13.364.4 6.362.4 10.663.0 0.560.4 0.860.7
Tonsillar Lymphoid
suspension cells
19.561.5 3.861.1 67.067.2 0.660.27 0.360.07 0.560.09 1.060.58
doi:10.1371/journal.pone.0001999.t001
TLR8mediated Anti-HIV activity
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assay in which one cell line expresses CD4 and CCR5 and another
cell line expresses CCR5-tropic gp120, we have not observed any
non-specific blocking of HIV fusion from the compounds examined
(Fig. 6A). Notably, HeLa cells do not express TLR7 or 8.
Expression level of the HIV receptor complex is required for
HIV to enter a cell. Indeed, we found that triggering TLR8 and/
or 7/8 resulted in a decrease in the percentage of CD4+ cells
expressing CCR5 while the percentage of CD4+ cells expressing
CXCR4 was unchanged (Fig. 6B). The median intensity of CCR5
and CXCR4 was not affected by triggering TLR7 and/or 8 (data
not shown). The decrease of CCR5 may be explained by the
increased release of b-chemokines. However, X4-tropic HIV
strains were inhibited to the same extent as R5-tropic strains.
Thus, other anti-HIV active mechanisms must be blocking HIV
replication. Additionally, we used a lentiviral based reporter virus
pseudotyped with the envelope from vesicular stomatitis virus.
This virus uses an entirely different entry mechanism than HIV
and was inhibited to the same extent as HIV when the tissue was
treated with compounds triggering either TLR7 and/or TLR7/8
(Fig. 6D).
We further wanted to substantiate the above-mentioned
findings using an experimental set-up that examines whether the
TLR7/8 agonists induced effects inhibits HIV replication at the
level of transcription or later in the HIV replication cycle. For this
purpose, we infected isolated CD4+ T-cells with HIV using
spinoculation [21] and added 12 h later the fusion inhibitor
enfurvitide which prevents spreading infection. Spinoculation was
used to increase the number of HIV infected CD4+ T-cells which
Table 2. Measurement of cytokines (pg/ml) one day after triggering TLR7 and/or 8 in unfractionated PBMC and PBMC without DC
(n = 2).
control 3M-001 3M-002 R-848
IFN-a Unfractionated PBMC ,8; 9.6 3624; 5950 1057; 499 1989; 4250
PBMC without DC ,8; ,8 ,8; 53.8 9.6; 17.2 9.6; 37.2
IL-12 (p40) Unfractionated PBMC 32; 19 1564; 1168 13608; 5777 12784; 5591
PBMC without DC 101; 190 146; 56 185; 264 129; 190
IL-15 Unfractionated PBMC ,0.1; ,0.1 0.59; 0.46 0.42; 0.21 0.52; 0.3
PBMC without DC ,0.1; ,0.1 ,0.1; ,0.1 ,0.1; ,0.1 0.1; ,0.1
IL-18 Unfractionated PBMC 37; 16 46; 24 615; 590 253; 333
PBMC without DC ,0.1; 1.3 ,1; 1.8 6.1; 24.1 6.1; 15.4
TNF-a Unfractionated PBMC ,0.9; ,0.9 56; 101 37659; 33474 40332; 20478
PBMC without DC 407; 1647 429; 727 586; 1397 56; 1482
All data presented in this table were measured by bead assay as described in the Material and Method section.
doi:10.1371/journal.pone.0001999.t002
Table 3. Induction of cytokines (pg/ml) two days after triggering TLR7 and/or 8 in MoMDC; indicated are the average6std fold
induction# and the individual absolute concentrations of cytokines measured in the supernatant [pg/ml] ".
control 3M-001 3M-002 R-848
IFN-c 0, 0.2, 0, 0" 1
0,0,0.2,4.2" 0.4, 0.8 , 0, 0 0, 0.2, 0, 0
IL-6 139, 150, 163, 100 1.160.3# 168697 1636291
209, 168, 168, 79" 40000, 12650, 34078, 9318 83336, 1048, 6730, 496
IL-8 33558, 2708, 1117, 2199 1.160.7 73673 15613
3094, 3963, 1132, 3558 98638, 125298, 195580, 146220 20395, 20675: 28866, 56422
IL-12 63, 299, 61, 85 1.861.5 1.561.1 1.560.8
229, 5.4, 107,158 147, 69, 153, 71 123, 241, 147, 63
TNF-a 4.6, 0.2, 3.4, 10 4.063.3 5116913 996124
20.2,1.6,0.4,33.8 292, 376, 253, 261 233, 56, 196, 77
MIP-1a 45, 12, 45, 12 1.160.8 91686 9.0612
12, 22, 32, 22 7085, 360, 184, 2034 133, 74, 22, 319
MIP-1b 609, 9.2, 49, 72 1.060.5 1468.0 7.867.1
277, 15, 49, 72 9633, 90, 298, 1811 1967, 123, 9.2, 1021
RANTES 8, 2.2, 8, 2.2 1.160.5 33.17628.44 14.26616.62
6, 2.2, 6, 4 584, 23, 123, 75 36, 31, 6, 83
1: induction can not be calculated since denominator is 0.
All data presented in this table were measured by enzyme immunoassay as described in the Material and Method section.
doi:10.1371/journal.pone.0001999.t003
TLR8mediated Anti-HIV activity
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will increase the sensitivity of the read out. Thereafter, we co-
cultured these infected CD4+ T-cells with autologous PBMC
devoid of CD4+ T-cells which had been previously exposed to the
TLR7/8 agonists. In this setup, the resulting HIV production was
solely due to the ongoing HIV transcription of the CD4+ T-cells
being already infected. If the changes in the microenvironment
induced had any effect on HIV replication after integration, we
would see a clear decrease of resulting HIV replication in samples
treated with the TLR agonists. However, this was not the case
(Fig. 6E), indicating that they display their inhibitory activity prior
to integration of HIV into the host chromosome.
Discussion
We previously showed that triggering TLR7/8 causes changes
to the lymphoid microenvironment that are unfavorable for HIV
replication [12]. Here we sought to identify the individual
contributions of TLR7 and 8 to the overall anti-HIV activity
and to gain insights into the mechanisms of how TLR trigger anti-
viral defenses. We found that (i) the TLR7- or 8-mediated anti-
HIV activity depended on the origin of the lymphoid tissue, (ii)
dendritic cells are indispensable for the anti-HIV effect, (iii) the
main effector cells for the anti-HIV activity were NK-cells and
CD8+ T-cells, and iv) soluble factors mediated the anti-HIV
effects and were not reversed when the antiviral active cytokines
IFN-a, -c, or TNF-a were neutralized.
The TLR7/8 agonist R-848 shows strong anti-HIV activity in
PBMC and lymphoid suspension cells from tonsils [12]. In this study,
we used two agonists which selectively trigger either TLR7 or 8 [22].
Their potency depended strongly on the origin of lymphoid tissue.
Triggering TLR7 was primarily responsible for the anti-HIV activity
in tonsillar lymphoid suspension cells, but it had only limited and
inconsistent effects in PBMC. In contrast, triggering TLR8 had
strong anti-HIV activity in PBMC; it had also consistent but
somewhat less anti-HIV activity in tonsillar lymphoid suspension
cells. Because of limited availability of tonsillar tissue, we focused in
most experiments on PBMC for elucidating the anti-HIV mecha-
nism(s) of TLR7 and/or 8 triggering.
Based on the sentinel function and the expression of TLR8, we
speculated that MDC initiate the complex changes in PBMC that are
eventually unfavorable for HIV replication. Indeed, when we
depleted DC and DC precursors from PBMC, the anti-HIV effect
from TLR7/8 triggering was mostly lost. Not surprisingly, depletion
of these cell subsets from untreated cultures resulted in modest
increases of HIV replication, pointing to HIV’s ability to trigger TLR
directly [5,23,24] and thus to initiate an anti-viral defense program,
although less potently than the TLR agonists examined. The potent
antiviral defense program initiated by TLR8 or 7/8was also reflected
when exposing MoMDC to the TLR agonists: they showed cell
clumping, up-regulation of the cell surface marker CD80, CD83 and
CD86 as well as pronounced secretion of a number of cytokines.
Triggering solely TLR7 had no visible effect on MoMDC.
Figure 3. NK cells and CD8+ T-cells are the effector cells responsible for the anti-HIV effects in PBMC after triggering TLR8 or TLR7/
8. PBMC from different donors were either depleted of CD8+ T-cells or NK or both, treated with the various TLR7 and/or 8 agonists and infected with
the X4-tropic strain NL4-3 two days later. HIV infection was monitored by measuring p24 antigen in the supernatant over time. Statistical analysis was
done by paired t-test.
doi:10.1371/journal.pone.0001999.g003
TLR8mediated Anti-HIV activity
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Previously, we reported that depletion of B cells partially reversed
the anti-HIV activity of R-848 [12]. Strikingly, when we depleted
NK and CD8+ T-cells prior to adding the TLR8 or 7/8 agonists to
PBMC, we observed a rather complete reversal of the anti-HIV
effects; depleting either NK or CD8+ T-cells showed only partial
inhibition, suggesting that there is an additive effect when stimulating
NK and CD8+ T-cells or there is an eminent cross-talk between
these cell-populations necessary for this striking anti-HIV effect.
Triggering TLR7 in PBMC depleted from NK and CD8+ T-cells
showed inconsistent effects which reflect its overall inconsistent anti-
HIV effects. Since NK and CD8+T-cells are the key effector cells for
the TLR8-mediatedHIV inhibitory activity, their low or even absent
numbers in tonsillar lymphoid suspension cultures may explain the
lower TLR8 agonist’s anti-HIV effects in that tissue as compared to
PBMC. The robust HIV inhibitory activity in tonsillar lymphoid
tissue and the rather poor one in PBMC in response to TLR7
triggering speak in favor of additional tissue type specific
mechanism(s) beyond NK and CD8+ T-cells which may explain
the differences between TLR7 and TLR8 agonists. Notably, while
we have not assessed functional differences, the percentages of DC
are similar in the lymphoid tissue studied.
The potent cell activation subsequent to triggering TLR8 or
TLR7/8 is reflected by an up-regulation of intracellular IFN-c
and TNF-a and increased cytolytic activity of NK and CD8+ T-
cells. Surprisingly, levels of expression of inhibitory (CD94,
KIR2DL2, KIR3DL1, ILT2) and activating receptors (NKp30,
NKp46, NKp44, DNAM-1) on NK cells were similar between the
controls and PBMC treated with TLR agonists (data not shown).
Since NK and CD8+ T-cells do not respond directly to TLR7/
8 agonists [25], their activation has to occur either by cell-cell
contact with a TLR7/8-responsive cell or by soluble factors. The
most likely candidates are IL-12, -15, and -18, which are released
from DC upon their activation. However, blocking the individual
cytokines or all of them with neutralizing antibodies did not
reverse the anti-HIV activity and neither prevented the cellular
activation of NK and CD8+ T-cells that is consistent with a
recently published study [26]. Thus, we assume that cell-cell
contact and/or a variety of soluble redundant factors will
ultimately result in the activation of these effector cells. Indeed,
the significance of bi-directional interactions between DC and NK
cells has been convincingly demonstrated for an efficient immune
defense [17,18].
Figure 4. Triggering TLR8 or 7/8 results in strong activation of NK and CD8+ T-cells. PBMC were treated with the TLR agonists and 24 h
later analyzed for intracellular IFN-c, TNF-a and CD107a expression for CD8+ T-cells (A) and NK (B), for the expression of CD69 on NK cells (n = 3) (C)
and for the NKs’ cytolytic activity against K562 cells (n = 3) (D). Data were first analyzed by one-way analysis of variance and if tested significantly
different, by Bonferroni’s multiple comparison test.
doi:10.1371/journal.pone.0001999.g004
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So how do NK and CD8+ T-cells block HIV infection? To
answer this question, we used trans-well experiments, in which
HIV-infected CD4+ T-cells were separated from PBMC devoid of
CD4+ T-cells. We found that separating the effector from the
target cells did not abrogate the anti-HIV effects, thus implicating
soluble factors in the process. Indeed, triggering TLR7 and/or 8
resulted in prominent changes in the cytokine profile. However,
we were not able to assign the anti-HIV effect to one distinct
Figure 5. Soluble factors are critical to the anti-HIV effects after triggering TLR8 and 7/8. (A) Isolated CD4+ T-cells of PBMC were infected
with HIV overnight. Transwells were added with the purpose to separate the HIV infected CD4+ T-cells by a semi-permeable membrane (indicated by
the dashed line) from autologous uninfected PBMC devoid of CD4+ T-cells. TLR agonists were added to the culture medium as indicated in the figure.
Infected PBMC where the TLR agonists were added to the insert served as positive control for the TLRs’ efficient antiviral activity. Notably, CD4+ T-
cells do not express TLR7 and 8 and thus do not react to the TLR agonists added. In this setup any inhibitory HIV activity observed when HIV infected
CD4+ T-cells were separated by a semi-permeable membrane from the PBMC (devoid of CD4+ T-cells) must be due to factors secreted by the PBMC
into the medium, which then diffuse through the semi-permeable membrane (n = 3). This setup with separated cells was compared to PBMC which
have been treated identically. Control indicates PBMC infected with HIV. B) Blocking the IFN-a/b receptor (IFN-a/b R) does not reverse the TLR7/8
triggering mediated inhibition of HIV. Neutralizing antibodies to IFN-a/b R was added at 10 mg/ml 30 minutes prior to R-848 to PBMC which was
infected two days later with HIV. All values were indicated as relative to the matched control which was arbitrarily set to 1.
doi:10.1371/journal.pone.0001999.g005
Table 4. Induction of cytokines one day after triggering TLR7 and/or 8 in PBMC; indicated in each box upper line are the
average6std fold induction# and lower line the corresponding absolute concentrations of cytokines measured in the supernatant
[pg/ml] (n = 3) ".
control 3M-001 3M-002 R-848
IFN-a ¥ 46, 0.1, 0.1" 152061931# 4276738# 154461680#
1000, 370, 84" 64, 128, 0.1 562, 334, 128
IFN-c ¥ 191, 81, 53 0.860.2 1.661.0 1.360.4
185, 50, 41 507, 50, 79 306, 75, 79
IL-6 ¥ 3638, 2834, 1555 2.760.6 1.760.2 2.460.3
7534, 7960, 5174 5731, 5464, 2301 7298, 7168, 3994
IL-8 ¥ 14813, 14127, 15245 1.060.2 0.960.1 0.860.2
17587, 15029, 11342 15529, 12319, 11717 13599, 13515, 9427
MIP-1a ¥ 131, 52, 37 3.061.7 1.860.4 2.660.9
194, 139, 176 176, 115,72 221, 135, 128
MIP-1b ¥ 275, 84, 25 5.966.2 3.061.9 5.164.5
344, 299, 327 394, 208, 129 479, 286,257
RANTES ¥ 134, 32, 14 7.664.1 3.060.3 7.063.0
646, 186, 172 356, 102, 42 646, 186, 146
IL-12 (p40) * 83, 30, 100 4.662.1 43.6615.0 21.969.0
531, 69, 516 3331, 1803, 3069 1710, 943, 1366
TNF-a * 685, 938, 529 1.960.6 36.7612.1 19.065.7
1122, 1449, 1357 30779, 21380, 22470 17560, 14698, 8372
* ¥ IFN-a, IFN-c, IL-6, IL-8, MIP-1a, MIP-1b, RANTES were measured by enzyme immunoassays, IL-12(p40) and TNF-a were measured with a bead assay (see material and
method section).
doi:10.1371/journal.pone.0001999.t004
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cytokine even though we neutralized a large number of soluble
factors either alone or in combination. The lack of any reversal of
the antiviral activity subsequent to triggering TLR8 or TLR7/8
when IFN-a was neutralized is most puzzling and speaks in favor
of very potent unknown factor(s) inhibiting HIV. In contrast, the
inhibitory activity in response to TLR7 triggering was partially
reversed when IFN-a was neutralized: this indicates that these
above postulated factor(s) are not secreted or not to the same
amount when exposing lymphoid tissue to TLR7 agonists. While
not statistically significant, it appeared that blocking IL-12, -15
and -18 resulted also in some reversal of the anti-HIV effects in the
case of triggering TLR7. We assume that TLR7 triggering
activates DC which in turn releases IL-12, -15 and -18 critical for
activating downstream effector cells such as NK or CD8+ T-cells.
While the data with the trans-wells were unambiguous, cell-cell
contact may substantiate the anti-HIV effects. However, NK cells
showed only minor changes of activating and/or inhibiting
receptors (see above) and thus, we do not assume that they play
a major role. In contrast, TRAIL showed a prominent up-
regulation on NK cells. This increased TRAIL expression is
reminiscent of a recent report describing the TLR7 triggering
dependent generation of killer PDC expressing TRAIL able to
induce apoptosis of HIV-infected SupT1 cells [27]. The potential
effects of TRAIL may be masked by the potent inhibitory anti-
HIV effects of soluble factors in our experimental set-up that may
explain the lack of any reversal of anti-HIV activity when
neutralizing TRAIL (data not shown). The potent HIV-inhibition
by soluble factors is reminiscent of the long-searched CD8+ T-cell
antiviral factor, CAF [28].
Triggering TLR7/8 appears to inhibit HIV before its
integration into the host-genome. Downregulation of CCR5 after
release of b-chemokines may contribute to the anti-HIV activity
when challenging the lymphoid tissue with CCR5-tropic strains.
However, other anti-HIV mechanism(s) must be involved. Down-
regulation of CCR5 was not complete, and more importantly, X4-
tropic strains were also inhibited. We excluded an unspecific effect
on the fusion process of the TLR agonists as examined by a cell-
cell based fusion assay. Furthermore, we used replication-
incompetent viruses pseudotyped with VSV envelope, which enter
cells by an entirely different mechanism(s) than HIV. We observed
Table 5. Neutralization of cytokines had no impact on anti-HIV activity subsequent to triggering TLR8 and/or 7/8; indicated are the
percent inhibition of anti-HIV activity (median (25 to 75% percentile).
nAb to 3M-001 3M-002 R-848
Ø + Ø + Ø +
IFN-c; (n = 4) 26.52 5.195 87.28 89.8 81.9 76.39
(13.92 to 55.05) (253.89 to 43.42) (80.8 to 92.15) (66.68 to 93.46) (73.03 to 90.22) (69.78 to 86.03)
IFN-aR; (n =6) 14.08 67.4# 83.75 90.42 91 91.15
(25.85 to 48.7) (11.54 to 82.79) (68.43 to 91.81) (77.7 to 97) (69.49 to 91.81) (76.16 to 95.41)
IFN-aR/IL-12; (n =3) 7.16 3.43 89.65 68.86 94.63 80.24
(218.86 to 12.42) (217.64 to 14.28) (77.85 to 93.29) (217.63 to 96.64) (93.46 to 94.87) (51.99 to 96.38)
IL-12; (n =6) 39.22 59.58 78.95 84.6 78.02 82.77
(235.8 to 65.03) (12.13 to 71.96) (66.53 to 88.95) (72.83 to 92.96) (74.74 to 93.71) (79.58 to 94.72)
IL-15; (n =19) 57.3 25.9 77.1 80.5 77.3 78.4
(20.7 to 62.3) (274.5 to 71.8) (70.3 to 81.8) (67.7 to 85.2) (70 to 83.9) (69 to 83)
IL-12/IL-15/IL-18; (n = 6) 39.22 63.46 78.95 81.14 78.02 81.16
(235.8 to 65.03) (21.24 to76.5) (66.53 to 88.95) (67.77 to 93.14 (74.74 to 93.71) (75.65 to 94.72)
IL-12/IL-15; (n = 6) 39.22 66.94 78.95 87.51 78.02 86.27
(235.8 to 65.03) (7.645 to 80.42) (66.53 to 88.95) (80.7 to 94.21) (74.74 to 93.71) (80.19 to 95.8)
IL-12/IL-18; (n = 6) 39.22 63.58 78.95 77.92 78.02 79.87
(235.8 to 65.03) (17.71 to 73.26) (66.53 to 88.95 (54.59 to 92.16) (74.74 to 93.71) (69.7 to 93.25)
IL-15/IL-18; (n = 6) 39.22 59.17 78.95 77.4 78.02 72.14
(235.8 to 65.03) (2.365 to 66.42) (66.53 to 88.95) (51.38 to 92.02) (74.74 to 93.71 (52.17 to 91.98)
IL-18; (n =6) 39.22 64.95 78.95 80.56 78.02 78.81
(235.8 to 65.03) (0.275 to 79.42) (66.53 to 88.95) (63.29 to 93.67) (74.74 to 93.71) (66.42 to 94.34)
MIP-1a; (n = 4) 43.91 38.39 87.28 86.37 81.9 81.83
(13.91 to 72.56) (14.07 to 66.64) (80.8 to 92.15) (81.85 to 91.57) (73.03 to 90.22) (69.36 to 89.27)
MIP-1b; (n = 4–6) 26.39 36.17 89.79 74.64 81.9 65.26
(13.91 to 54.92) (218.75 to 64.47) (80.8 to 93.78) (212.02 to 88.91) (73.03 to 90.22) (49.54 to 82.02)
RANTES; (n=4) 26.39 10.73 87.28 87.4 81.9 77.94
(13.91 to 254.56) (2125.1 to 66.67) (80.8 to 92.15) (69.98 to 91.5) (73.03 to 90.22) (63.78 to 90.21)
SDF-1; (n =4–6) 35.56 28.055 87.28 89.64 81.9 79.11
(13.91 to 55.4) (2144.1 to 48.93) (80.8 to 92.15) (66.33 to 93.3) (73.03 to 90.22) (59.21 to 88.18)
#P= 0.012 (paired T-test)
doi:10.1371/journal.pone.0001999.t005
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Figure 6. Triggering TLR8 and/or 7/8 blocks HIV replication after HIV entry but before integration. (A) Unspecific inhibitory effects of the
compounds triggering TLR7 and/or 8 on HIV entry was examined with a cell-cell-based fusion assay, in which one cell line expresses the HIV-gp120
and an LTR-driven lacZ gene (HeLa SX CCR5) and the other cell line expresses the HIV receptor complex (CD4 and CCR5) and Tat (HeLa 243). Fusion of
these cell lines will result in Tat driven LTR lacZ gene expression which we quantified histochemically by staining for b-galactosidase activity (n = 2). (B
and C) Percentage of C4+ T-cells expressing CCR5 and CXCR4 was quantified by flow-cytometry two days after triggering TLR7 and/or 8 of PBMC
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a similar inhibition of the reporter gene in tissue exposed to TLR
agonists, also suggesting that these agonists act after entry but
before integration/transcription. To substantiate this finding, we
investigated whether the TLR agonists induced changes influence
HIV replication at the level of transcription: for that purpose
CD4+ T-cells were infected overnight and spreading infection was
inhibited by adding the fusion inhibitor enfurvitide. The infected
CD4+ T-cells were subsequently co-cultured with previously
TLR7/8 agonist stimulated autologous PBMC devoid of CD4+ T-
cells. Thus, resulting HIV output from this co-culture reflects
exclusively HIV transcription from HIV-infected CD4+ T-cells. In
this setup, the TLR agonists had no inhibitory activity as
compared to the control excluding any inhibitory action at the
transcriptional level.
In summary, we propose a new model, in which triggering
TLR7 and/or 8 of DC activates NK cells and CD8+ T-cells.
These cells, in turn, induce the release of soluble factors that result
in a microenvironment unfavorable to HIV infection. Since B cells
express TLR7, they may be activated directly or indirectly by the
corresponding trigger, but in any case, they have less anti-HIV
activity than NK and CD8+ T-cells. The inability to identify a
specific soluble factor is characteristic of the vast array of changes
induced by triggering pattern recognition receptors and points to
the poorly understood redundancy of the innate immune
responses. As outlined in the introduction, we would like to
reiterate the fact that compounds triggering TLR7 and/or 8 also
strengthen the adaptive immune responses. Thus, these com-
pounds may combine by acting on diverse arms of the immune
response optimal properties as immunomodulatory drugs in HIV
infection.
Materials and Methods
Primary lymphoid tissue, cell lines, separation of cells,
and generation of monocyte-derived myeloid dendritic
cells
PBMC obtained from the blood bank (Stiftung Zu¨rcher
Blutspendedienst SRK, Zu¨rich, Switzerland) were prepared by
Ficoll Hypaque and cultured in RPMI (BioWhittaker, Verviers,
Belgium) supplemented with 10% fetal calf serum (PAA Laborato-
ries, Vienna, Austria), 10 U/ml IL-2 (National Institutes of Health,
AIDS Repository), 2 mM L-glutamine (Invitrogen Life Technolo-
gies, Paisley, Scotland), and 1% penicillin/streptomycin (Invitrogen
Life Technologies). We were authorized by the Ethical Committee of
the University Hospital Zurich to receive tonsillar tissue from the
Department of Otorhinolaryngology, University Hospital of Zurich.
Tonsillar tissue was minced and subsequently put into a cell strainer
(70 mm; BD Biosciences, San Jose, CA) where the tissue was grinded
through the sieve with a syringe plunger. Erythrocytes were lysed
with ACK cell lysing buffer (Cambrex, Walkersville, MD).
Lymphoid cells were washed. These lymphoid suspension cells were
cultured in RPMI containing 15% FCS, 1% penicillin/streptomy-
cin, 2.5 mg/ml Fungizone, 2 mM L-glutamine, 1 mM sodium
pyruvate, and 1% nonessential amino acids. HeLa (ATCC#CCL 2)
and 293 T (ATCC #CRL 1573) cells were cultured in DMEM
(10% FCS, 1% penicillin/streptomycin), EGFP-K562 [29] cells in
RPMI resp. supplemented with 10% FCS, 2mM glutamine and 1%
penicillin/streptomycin. G418 was in addition added to the RPMI as
antibiotic selection for EGFP-K562 cells for guaranteeing transgene
EGFP expression.
To deplete PBMC from a distinct cellular subset, we used
MicroBeads from MACS Miltenyi (Bergisch Gladbach, Germany).
Specifically we used CD56 MicroBeads for NK cells, CD4
MicroBeads for CD4+ T-cells and CD8 MicroBeads for CD8+ T-
cells. To sort for PBMC lacking dendritic cells (DC) or their
precursors, PBMC were stained with antibodies to the lineage
markers CD3, CD19, CD56 and CD14, labeled to FITC, and to
the cell-surface markers HLA-DR and CD16, and subsequently
sorted for the lineage-positive but CD16-negative cell population
on a FACS Aria as previously described [30]. Efficacy of depletion
was always .95% as verified by flow cytometry.
To generate monocyte-derived myeloid dendritic cells
(MoMDC), we cultured monocytes which were isolated using
CD14 microbeads in RPMI supplemented with 1000 U/ml each
of GM-CSF and IL-4 for 6 days. IL-4 and GM-CSF were
purchased from ImmunoTools (www.immunotools.de). The
MoMDC had a purity of .93% as defined by the cell surface
expression of CD11c using flow-cytometry and were cultured at a
density of 16106/ml.
Reagents and antibodies for neutralization of cytokines
The TLR ligands 3M-001, 3M-002, and R-848 were generously
provided by 3M Pharmaceuticals (St. Paul, Minnesota). The
following antibodies were used: mAb anti-human interferon-a/b
receptor chain 2 at 10 mg/ml (clone MMHAR-2, PBL Biomedical
Laboratories, purchased from Alexis, Lausen, Switzerland), anti-
human IL-18 at 100 ng/ml (clone 125-2H; MBL Medical &
Biological Laboratories), anti-human IL-15 at 500 ng/ml (clone
34559; R&D), anti-human IL-12 at 20 ng/ml (ab9992, Abcam,
Cambridge, UK), anti-human MIP-1a at 4 mg/ml (ab10381
Abcam), anti-human MIP-1b at 3 mg/ml (#PP1051, Acris,
Hiddenhausen, Germany), anti-human Rantes at 7 mg/ml
(ab9679, Abcam), anti-human IFN-c at 100 ng/ml (ab9657,
Abcam) and anti-human SDF-1a at 5 mg/ml (#PP1067, Acris,
Hiddenhausen, Germany).
Colometric viability assay
The Colorimetric Cell Viability WST-1 kit (Roche, Mannheim,
Germany, Cat. No 1 664 807) is based on the metabolism of the
tetrazolium salts to water-soluble, orange formazan dyes by
dehydrogenases present in viable cells. The WST-1 kit was used
according to the instruction of the provider.
HIV strains
We used the prototype HIV strains NL4-3, 49.5, JR-CSF and
89.6; all were proviral DNAs. To generate viral stocks, 293 T cells
were transfected with proviral DNA by polyethylenimine (PEI),
and supernatants were harvested 2 days later, passed through a
0.22-mM filter, and stored at -80uC until use.
Dashed lines indicate the matched samples. (D) Replication incompetent lentiviral viruses pseudotyped with VSV envelope which encodes a
luciferase reporter gene were used to assess whether TLR7 and/or 8 triggering affects the early step in the replication cycle of HIV. Notably VSV uses a
totally different entry mechanism than HIV which is highly unlikely to be affected by the TLR7 and/or 8 agonists. (E) Assessment whether TLR agonists
have any effects on HIV replication at the transcriptional level or later in the HIV replication cycle. For this purpose, CD4+ T-cells were infected with
HIV and spreading infection was blocked by adding the fusion inhibitor enfurvitide. These CD4+ T-cells with integrated HIV were co-cultured with
either autologous PBMC devoid of CD4+ T-cells previously stimulated by TLR7 and/or 8 agonists vs unstimulated autologous PBMC devoid of CD4+ T-
cells. Thus, any change in HIV output would be due to the effects on either transcription or later events in the HIV replication cycle due to TLR7 and/
or 8 triggering (analysis of variance: n.s.; n = 6).
doi:10.1371/journal.pone.0001999.g006
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Infectivity assays
PBMC or tonsillar lymphoid suspensions cells were cultured in
wells of 96-well plates at a concentration of 106106 cells/ml,
pretreated for 2 days with the corresponding TLR agonist,
according to the specific aim of the experiment, and subsequently
infected overnight with 1–3 ng HIV/well. Cultures were exten-
sively washed, and new medium was added with the correspond-
ing agonists. HIV replication was monitored by quantifying p24
over time by an in-house p24 ELISA [31].
When we assessed the role of distinct cytokines for their
significance in blocking HIV replication, we added the neutral-
izing antibodies (concentrations see above) 30 minutes prior to the
TLR7/8 agonists.
Effects of TLR ligands on transcription or later stages of HIV
replication were examined in a co-culture assay where HIV-infected
CD4+ T-cells were cultured with autologous PBMC depleted of
CD4+ T-cells. The CD4+ T-cells were infected by spinoculation
with HIV [21] and kept overnight. The autologous PBMC depleted
of CD4+ T-cells were activated prior to the co-culture by the TLR7
and/or 8 agonists. We added the fusion inhibitor enfurvitide at
50 mg/ml to the co-culture in order to prevent spreading infection.
Thus, this experimental set-up permits to assess the effects of the
TLR7 and/or 8 agonists on HIV replication at the level of HIV
transcription or later in the HIV replication cycle.
For inter-donor comparisons, we expressed the p24 values over
time as the area under the curve (AUC) representing HIV
replication. We calculated the percent inhibition of replication by
any given drug and concentration by first expressing the AUC of
treated cultures as a percentage of an untreated, infected control
culture and then subtracting the percent of AUC treated samples
from 100%. In some experiments, we also expressed effects of TLR
ligands on HIV replication as fold change compared to the control.
NK-cytotoxicity assay
PBMC treated with the compounds that trigger TLR7 and/or 8
were co-cultured with the NK cell–responsive cell line EGFP-
K562 [29] at an effector : target ratio of 1:10 for 6 h. The
expression of enhanced green fluorescent protein (EGFP) allowed
us to precisely quantify the number of residual EGFP-K562 cells.
NK cytotoxic activity was calculated by expressing the residual
EGFP-K562 cells as a percentage of the initial number of target
cells added to the co-culture.
Flow cytometry
Monoclonal antibodies (mAb) to the following markers were
used: IFN-c (554552), TNF-a (559321), CD107a (555801), CD4
(555346), CD8 (555634), CD69 (555533), CD56 (555518 and
345811), CD80 (557227), CD83 (556855), CD86 (555658),
CD226 (559789), CD336 (558563), CXCR4 (555974), CCR5
(556903), CD3 (555339), CD19 (555412), CD14 (555397), HLA-
DR (340549), CD20 (559776), CD11c (333144) and CD123
(340545) (all from BD Pharmingen), CD16 (130-091-246;
Miltenyi), NKp30 and NKp46 (Beckman Coulter, Krefeld,
Germany), NKG2D (R&D Systems, Abingdon, UK), and CD94
(provided by L. Lanier, University of California, San Francisco,
CA). Quantification of DC was done by staining PBMC with the
lineage kit (Lin1 FITC 340546) and mAB against CD11c, CD123
and HLA-DR. To stain for intracellular cytokines, we used the
Cytofix/Cytoperm Kit (BD, #554714), according to the manu-
facturer’s instructions. Staining for CD107a was done by
incubating TLR7- and/or 8-treated PBMC with a mAb to
CD107a and Brefeldin A (BD Pharmingen, Allschwil, Switzerland)
for 5 h. Data were acquired on a FACS Calibur and analyzed by
FlowJo software (TreeStar)).
Transwell experiments
To determine if cell-cell contact or soluble factors are involved
in the anti-HIV effects after TLR triggering, HIV-infected CD4+
T-cells were cultured at the bottom of a well of a six-well plate, and
the PBMC devoid of CD4+ T-cells in the insert. As controls served
untreated PBMC infected with HIV as well as PBMC infected
similarly as the CD4+ T-cells which were placed at the bottom of
wells and the TLR agonists added to the inserts. Inserts with a
pore size of 4 m were purchased from Millipore. The compounds
triggering TLR were added to the medium. CD4+ T-cells do not
respond to TLR7/8 since they have no TLR7/8. Thus, any
observed effects must be due to soluble factors released from the
treated PBMC devoid of CD4+ T-cells.
Cytokine measurement
In the initial experiments, IL-6 (D6050), -8 (D8050), -12
(D1200), TNF-a (HSTA50), RANTES (DRN00B), MIP-1a
(DMA00), and -b (DMB00) were quantified by enzyme immuno-
assays (Quantikine ELISA, R&D Systems), according to the
manufacturer’s instructions, IFN-a (Bender Med Systems
BMS216) and -c (Hycult Biotechnology, Hbt human Interferon
gamma, HK030S) were quantified by enzyme immunoassays from
Bender MedSystems Diagnostics and HyCult Biotechnology,
respectively. We then changed to multiplexed particle-based flow
cytometric cytokine assay for measuring cytokines [32]. Bioplex
cytokine kits were purchased from BioRad (Ismaning, Germany).
The procedures closely followed the manufacturer’s instructions.
The analysis was conducted using a conventional flow cytometer
(FC500 MPL, BeckmanCoulter, Nyon, Switzerland). For each
data set, we have indicated what method was used.
Cell-based fusion assay
A cell-based fusion assay consisted of HeLa cells that express
gp140 from LAI and the HIV transactivator tat (HeLa-Env/LAI)
[33] and HeLa cells that express CD4 and the LTR-driven lacZ gene
(HeLa SX CCR5) [34]. Fusion of HeLa-Env/LAI cells and HeLa
SX CCR5 results in transcription of the lacZ gene. The extent of
fusion was quantified by assaying b-galactosidase activity in cell
lysates (E2000; Promega, Wallisellen, Switzerland) or by histochem-
ical staining of cells for b-galactosidase activity (Roche Molecular
Biochemicals), according to the manufacturer’s instructions. HeLa-
Env/LAI cells were treated with the various compounds and the
HIV fusion inhibitor enfurvitide [35]. Subsequently, a similar
number of HeLa SX CCR5 cells were added to allow fusion to take
place. b-Galactosidase activity was assessed 12 h later.
Pseudotype virus preparation and challenge of cells with
pseudotype viruses
To prepare HIV pseudotype virus packaged by vesicular
stomatitis virus (VSV) Env, an HIV proviral construct encoding
a luciferase reporter gene (pNL4-3.Luc.R2E2) was cotransfected
with a VSV Env expression vector in 293T cells as described [36].
To determine permissiveness to entry by pseudotype viruses,
PBMC cultures were pretreated with R-848 for 1 day, exposed to
pseudotype virus overnight, and cultured for additional 2 days
before analysis. Luciferase expression was quantified with the
luciferase assay system from Promega.
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